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Abstract
Influenza virus evolves to escape from immune system antibodies that bind to it. We used
free energy calculations with Einstein crystals as reference states to calculate the difference
of antibody binding free energy (∆∆G) induced by amino acid substitution at each position in
epitope B of the H3N2 influenza hemagglutinin, the key target for antibody. A substitution
with positive ∆∆G value decreases the antibody binding constant. On average an uncharged to
charged amino acid substitution generates the highest ∆∆G values. Also on average, substitu-
tions between small amino acids generate ∆∆G values near to zero. The 21 sites in epitope B
have varying expected free energy differences for a random substitution. Historical amino acid
substitutions in epitope B for the A/Aichi/2/1968 strain of influenza A show that most fixed
and temporarily circulating substitutions generate positive ∆∆G values. We propose that the
observed pattern of H3N2 virus evolution is affected by the free energy landscape, the map-
ping from the free energy landscape to virus fitness landscape, and random genetic drift of the
virus. Monte Carlo simulations of virus evolution are presented to support this view.
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1 Introduction
Influenza A virus causes annual global epidemics resulting in 5–15% of the population being in-
fected, 3–5 million severe cases, and 250,000–500,000 fatalities.1 The subtype of influenza A is
determined by two surface glycoproteins—hemagglutinin (H) and neuraminidase (N). The H3N2
virus has been one of the dominant circulating subtypes since its emergence in 1968. The antibod-
ies IgG and IgA are the major components of the immune system that control influenza infection,
binding to the influenza hemagglutinin.2 There are five epitopes at the antibody binding sites on
the top of H3 hemagglutinin, namely epitopes A–E. The epitope bound most prolifically by anti-
body is defined as the dominant epitope, and it is central to the process of virus neutralization by
antibody and virus escape substitution.3 The cellular immune system, on the other hand, plays a
relatively less recognized role in handling the invasive influenza virus.2 The cellular system along
with the innate immune system exerts a somewhat more homogeneous immune reaction against
genetically distinct influenza strains.2,4
Vaccination is currently the primary method to prevent and control an influenza epidemic in
the human population.1 Influenza vaccination raises the level of antibody specific for hemagglu-
tinin and significantly enhances the binding affinity between antibody and hemagglutinin. Vaccine
effectiveness depends on the antigenic distance between the hemagglutinin of the administered
vaccine strain and that of the dominant circulating strain in the same season.3,5 Memory immune
response from virus in previous seasons as well as vaccination in the current and previous seasons
impose selective pressure on the current circulating virus to force it to evolve away from the virus
strains recognized by memory antibodies that selectively bind to hemagglutinin.
As a result of the immune pressure and the escape evolution of the influenza virus, which
is largely substitution in the dominant epitope of hemagglutinin, the influenza vaccine must be
redesigned and administered each year, and the vaccine effectiveness has been suboptimal in some
flu seasons.3,6 The escape evolution in the dominant epitope is at a higher rate than that in the amino
acid sites outside the dominant epitope.7 Sites in the dominant epitope also show higher Shannon
entropy of the 20 amino acids than do those outside the dominant epitope.8 High substitution
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rate and Shannon entropy in the dominant epitope of hemagglutinin suggest that the dominant
epitope is under the strongest positive selection by human antibodies. The immune pressure against
each genotype of the dominant epitope can be at least partially quantified by the binding constant
between antibody and hemagglutinin.
The H3N2 virus and human immune system in this work are simplified to be a system con-
sisting of the H3 hemagglutinin and the corresponding human antibody. Exposure by infection or
vaccination produces an affinity-matured antibody with the binding constant to the corresponding
hemagglutinin equal to 106–107 M−1, while the binding constant of an antibody uncorrelated to
the hemagglutinin is below 102 M−1.2 Escape substitutions may decrease the binding constant by
changing the antibody binding free energy ∆G. Some substitutions decrease the antibody binding
constant more than others and have higher probabilities to be fixed, because decrease in the anti-
body binding constant is favorable to the virus. Here we define the difference of antibody binding
free energy as ∆∆G = ∆G42 −∆G31 in which ∆G31 and ∆G42 are antibody-wildtype hemagglu-
tinin binding free energy and antibody-evolved hemagglutinin binding free energy, respectively, as
shown in Figure 1. The fixation tendency of each substitution is a function of the difference of the
antibody binding free energy9 of the escape substitution.
Epitope A or B of the H3N2 virus was dominant in most influenza seasons.3 Epitope B of
the H3N2 virus was the dominant epitope presenting more substitutions than any other epitope in
the recent years. Epitope B was also dominant in 1968 when H3N2 virus emerged. Thus during
these periods of time, the substitutions in epitope B directly affect the antibody binding constant
and reflect the direction of the virus escape substitution. To attain a global view of the effects
of substitutions in epitope B, it is necessary to compute a matrix containing the differences of
antibody binding free energy caused by each possible single substitution in epitope B. There are
21 amino acid sites in epitope B, and each residue in the wild type strain may substitute to any of
the 19 different types to amino acid residues, hence we need to calculate a 19×21 matrix with 399
elements. Such a matrix is a free energy landscape quantifying the immune selection over each
evolved influenza strain. In this free energy landscape, the virus tends to evolve to a position with
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low binding affinity of antibody to evade antibodies and reduce the immune pressure. Calculation
of this landscape will enable us to study the mechanism of immune escape from a quantitative
viewpoint, providing a criterion to describe and foresee the evolution of influenza virus.
This paper is organized as follows: In Materials and Methods section, we describe the protocol
for the free energy calculation and the system of hemagglutinin and antibody. In Results section,
we present and analyze the calculated free energy landscape. The substitutions observed in history
are also compared with the results of the calculation. In the Discussion section, a general pic-
ture of H3N2 virus evolution under the selection pressure of the immune system is discussed and
simulation results are discussed. Finally, our work is summarized in the Conclusion section.
2 Materials and Methods
2.1 Scheme of the Free Energy Calculation
The expression of the binding constant K depends on the antibody binding free energy ∆G, K =
exp(−∆G/RT ). The Boltzmann constant R = 1.987×10−3 kcal/mol/K. The temperature is fixed
to the normal human body temperature T = 310 K. Shown in Figure 1, one substitution in hemag-
glutinin changes the antibody binding free energy from ∆G31 to ∆G42. The first and second sub-
scripts define the end state and the starting state of the binding process, respectively. The ratio of
the antibody binding constant after and before substitution is written as
K1
K0
= exp(−∆∆G/RT ) (1)
where K1 and K0 are the antibody binding constant to substituted and wildtype hemagglutinin,
respectively.
The difference of the antibody binding free energy ∆∆G = ∆G42 −∆G31 = ∆G43 −∆G21 is
calculated by applying the Hess’ Law to the thermodynamic cycle defined by State 1–4 in Figure 1.
The processes corresponding to ∆G43 and ∆G21 are unphysical but more convenient to simulate.
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We calculated ∆G21 and ∆G43 for each amino acid substitution in the unbound hemagglutinin and
hemagglutinin bound by antibody, respectively. On the surface of the virus particle, hemagglutinin
exists in the form of a trimer in which three monomers are encoded by the same virus gene. Thus
we simultaneously substituted the amino acids in three hemagglutinin monomers in the trimer.
The antibody has a Y-shaped structure with two heavy chains and two light chains. In the resolved
structure (PDB code: 1KEN), the hemagglutinin trimer is bound by two Fab fragments. Thus, we
incorporated the Fab dimer into the system for MD simulation.
Using the software CHARMM,10 we calculated each of ∆G21 and ∆G43 using thermodynamic
integration.11 We used molecular dynamics (MD) simulation to obtain the ensemble averages of
the integrand from which each of ∆G21 and ∆G43 is calculated. The potential energy for the MD
algorithm to sample the conformation space of the system is
U (r,λ ) = (1−λ )Ureac (r)+λUprod (r) (2)
in which r is the coordinates of all the atoms, λ is the variable of integration, Ureac is the potential
energy of the system corresponding to wildtype hemagglutinin, and Uprod is the potential energy
of the system corresponding to substituted hemagglutinin. The value of ∆G21 or ∆G43 is
∆G =
∫ 1
0
〈∂U (r,λ )
∂λ
〉
λ
dλ =
∫ 1
0
〈
Uprod (r)−Ureac (r)
〉
λ dλ . (3)
The integrand
〈
Uprod (r)−Ureac (r)
〉
λ is the ensemble average with fixed λ of potential energy dif-
ference between the system after and before substitution. The interval of integration λ ∈ (0,1) was
equally divided into four subintervals in each of which a 16-point Gauss-Legendre quadrature was
applied to numerically integrate the ensemble averages. The ensemble averages with 64 distinct
λ ∈ (0,1) were calculated by MD simulation with the potential energy defined in Eq. (2).
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∆G31 ∆G42
Figure 1: The scheme of the free energy calculation. The free energy difference of one substitution
is calculated by ∆∆G = ∆G43 − ∆G21. State n, n = 1–4, is the real system. State na has the
same configuration of atoms as state n except that all the hydrogen atoms have mass 16.000 amu.
Compared to state na, state nb contains one additional Einstein crystal of product atoms (n = 1,3)
or reactant atoms (n = 2,4). The mass of hydrogen atoms in state nb is also 16.000 amu. Free
energy ∆G21b and ∆G43b are obtained by thermodynamic integration.
2.2 Einstein Crystal
We introduce the Einstein crystals to calculate the free energy of the reference state in the dual
topology at both endpoints of the thermodynamic integration. To illustrate the function of the
Einstein crystals, we analyze the free energy of the dual topology without Einstein crystals when
λ = 0 as an example. We denoted by n1, n2, and n0 numbers of the reactant atoms, product
atoms, and all the remaining atoms in the system, respectively. We denoted by r, rproduct, and x the
coordinates of the reactant atoms, product atoms, and all the remaining atoms in the system. The
momenta of reactant atoms, product atoms, and the remaining atoms are denoted by pr,i, pp,i, and
px,i. The masses are similarly denoted by mr,i, mp,i, and mx,i. The Hamiltonian of the system with
λ = 0 is
H =
n0∑
i=1
p2x,i
2mx,i
+
n1∑
i=1
p2r,i
2mr,i
+
n2∑
i=1
p2p,i
2mp,i
+Un0 (x)+(1−λ )Un0+n1 (x,r)+λUn0+n2
(
x,rproduct
)
. (4)
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The partition function is
Q =
n0∏
i=1
(
2pimx,i
h2β
)3/2 n1∏
i=1
(
2pimr,i
h2β
)3/2 n2∏
i=1
(
2pimp,i
h2β
)3/2
∫
dx dr exp [−βUn0 (x)−βUn0+n1 (x,r)]×
∫
drproduct 1
=Qreal×
n2∏
i=1
[(
2pimp,i
h2β
)3/2
V
]
=Qreal×Qproduct. (5)
When λ = 0, this partition function is the product of Qreal, the partition function of the real system
without product atoms, and Qproduct, the partition function of the product atoms when λ = 0.
The free energy is given by −1/β times the logarithm of the above partition function. The free
energy is
G = Greal−
1
β
n2∑
i=1
3
2
log
(
2pimp,i
h2β
)
−
1
β n2 logV. (6)
As shown in the above equation, the effect on the translational entropy from the product atoms is
proportional to the logarithm of system size V . It diverges in the thermodynamic limit. This diver-
gence exists, no matter what λ scaling is performed. Note that we do not use the Einstein crystals
to handle the translational entropy a ligand loses or gains when binding a flexible biomolecular
receptor, which is taken into account by the thermodynamic cycle in Figure 1. The translational
entropy, proportional to logV in Eq. (6), is that of the dummy product atoms, not that of the bound
or unbound complex.
The value of G depends on the identity of the product atoms. Thus, the contribution to the ther-
modynamic integration is different at the two endpoints, i.e. −kT logQreactant 6= −kT logQproduct,
in which Qreactant is the partition function of the reactant atoms when λ = 1. Note also that the
expression of the partition function contains the factor Qproduct for the product atoms. Relating the
conventional expression for thermodynamic integration, Eq. (3), to ∆∆G of Eq. (1) requires one to
account for this term. This term arises from the use of a dual topology in CHARMM, and this term
is typically ignored. While the contribution from the decoupled atoms is not constant, it can be
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exactly calculated if the restricted partition function over the decoupled atoms can be calculated.
This calculation is what the Einstein crystal performs, using an Einstein crystal for the reference
state rather the ideal gas in Eq. (4).
In four 16-window thermodynamic integrations, the smallest variable of integration is λ =
1.32×10−3. Since λ is close to zero, product atoms in the system have potential energy near zero
and behave as ideal gas atoms, with translational entropy proportional to the logarithm of system
size, see Eq. (6). Exact calculation of the translational entropy terms of product atoms at λ = 0
by explicit dynamics seems difficult, because the translational entropy of the product atoms grows
as the logarithm of the system size. These relatively free product atoms destabilize the system.
This entropy divergence is a fundamental feature of the statistical mechanics, not a numerical arti-
fact. Unrestrained product atoms induce large fluctuation of the Hamiltonian in the MD algorithm.
These fluctuations increase the standard error of the quantity Uprod (r)−Ureac (r), which is defined
in Eq. (3) and is computed from the trajectory of the MD simulation. These fluctuations often
cause the numerical integration algorithm in the MD simulation to be unstable.12 In this case, the
energy of the simulated system increases rapidly. This phenomenon causes CHARMM to termi-
nate abnormally. The translational entropy introduced by the free atoms at λ = 0 and 1 affects the
result. Reactant atoms cause the same problem near λ = 1.
We noticed that the non-linear scaling, i.e. using a high power of λ such as the fourth power
of λ , in Eq. (2)13,14 did not work. The high power of the smallest λ is extremely close to zero
and the product atoms are almost free, which cause the MD simulation to terminate abnormally
at several windows with small λ . Additionally, the issue of translational entropy of reactant and
product atoms needs to be addressed. Even when the MD algorithm with the non-linear scaling
of λ 13,14 terminates and appears to have generated a converged simulation trajectory, this does
not necessarily imply that the translational entropy of reactant or product atoms has been properly
controlled. In fact, the λ scaling approach may hide the entropy divergence at λ = 0 or λ = 1
by letting the algorithm terminate due to numerical roundoff error, rather than building statistical
mechanical reference states for each of λ = 0 and λ = 1 to account for or control the effect of
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translational entropy.
An alternative to λ scaling introduces the soft-core potential as a way to turn off the poten-
tial.15,16 The soft-core approach, like the lambda-scaling approach, does not address the translation
entropy of the atoms at λ = 0 or λ = 1. Previous studies with non-constrained atoms at both end-
points have been performed.17–23 Besides the classical molecular dynamics with a non-ideal-gas
reference state introduced into the dual topology, quantum molecular dynamics via metadynam-
ics has been used to analyze a deamidation process.24 Other applications of quantum molecular
dynamics based free energy calculation include chorismate conversion to prephenate,25 isomer-
ization of glycine,26 and histone lysine methylation.27 As illustrated in Eq. (6), the translational
entropy of the uncoupled atoms causes error in the final free energy results if it is not accounted
for.
One way to calculate the free energy change exactly is to use a non-ideal-gas reference state.
This is quite natural, since the protein is not composed of ideal gas atoms. Deng and Roux in-
troduced restraint potentials to confine the translational and rotational motion of a bound ligand
to accelerate convergence of the simulation.28 We use this idea to exactly include the contribution
from the restrained states and built two Einstein crystals as the reference states for reactant and
product atoms, respectively. Our calculation allows a theoretically exact determination of the free
energy due to amino acid substitution.
To handle these two difficulties at both endpoints of the integration in a theoretically exact way,
we use two Einstein crystals as the reference states for reactant and product atoms, respectively.
The Einstein crystal has been used as a reference state for free energy calculations. Frenkel and
Ladd computed free energy of solids by building a path connecting the real solid and the reference
Einstein crystal.29 Noya et al. showed that a restrained Einstein crystal is a suitable reference in the
free energy calculation of biomolecules.30 The Einstein crystal, a solid state model, is consistent
with the nature of antibody binding process in liquid phase. First, although the importance of
biomolecular flexibility in protein-protein binding process is well-accepted, and is fully and exactly
included in our calculation, we simply need to localize the product atoms when λ = 0 and the
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reactant atoms when λ = 1. Moreover, we need to calculate the contribution to the free energy of
these localized atoms.
The choice of Einstein crystals as the reference states removes the singularity in thermody-
namic integration in Eq. (3). As an example, an Einstein crystal was used as the reference state
for the free energy calculation of hard-sphere fluid in order to remove the singularity in Eq. (3) at
the end point λ = 0.31 In this example, the reference Einstein crystal was achieved by harmon-
ically coupling the particles to their equilibrium positions and removing all interactions between
particles.32
We here use Einstein crystals as the reference states to calculate the binding free energy change
due to amino acid substitution. The Einstein crystal is a model for localized atoms. The free energy
of the Einstein crystal can be exactly calculated. One Einstein crystal contains distinguishable and
non-interacting atoms under harmonic constraints around reference positions fixed in space. In the
Einstein crystal, the atom i with coordinates ri has potential energy
Ui (ri) =
Ki
2
‖ri− ri0‖
2 (7)
in which ri and ri0 are the actual and reference position of the atom, respectively, and Ki is the
force constant of the harmonic constraint. We denote by mi the mass of atom i. The canonical
partition function of an Einstein crystal is
QE (N,V,T ) = 1h3N
∫
exp
(
N
∑
i=1
−β p2i
2mi
)
exp
(
N
∑
i=1
−βKi ‖ri− ri0‖2
2
)
dp dr
=
(
2pi
hβ
)3N N
∏
i=1
(
mi
Ki
)3/2
. (8)
The spatial fluctuation of atom i in the Einstein crystal is
〈
(δ ri)2
〉
=
3
βKi . (9)
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In our system, we let the potential energy for MD simulation defined by Eq. (2) become
U (r,λ ) = (1−λ )Ureac (r)+λUprod (r)+λUein,reac (r)+(1−λ )Uein,prod (r) . (10)
Therefore reactant and product atoms are localized at both λ = 0 and λ = 1. The reference po-
sitions of atoms in Einstein crystals are the equilibrium positions of corresponding reactant and
product atoms. To minimize the numerical error during the thermodynamic integration calculation,
we minimized the fluctuation of the integrand of thermodynamic integration 〈∂U (r,λ )/∂λ 〉λ =〈
Uein,reac (r)−Ureac (r)
〉
λ +
〈
Uprod (r)−Uein,prod (r)
〉
λ . Minimization of the terms on the right hand
size is approximately achieved by letting the average spatial fluctuation of each atom in Einstein
crystals equal to that of the corresponding reactant or product atom, i.e.
〈
(δ ri)2
〉
reac
=
〈
(δ ri)2
〉
ein,reac
=
3
βKreaci
(11)
〈
(δ ri)2
〉
prod
=
〈
(δ ri)2
〉
ein,prod
=
3
βKprodi
(12)
For each atom in the Einstein crystal, the force constant of harmonic constraint, Kreaci or K
prod
i ,
was calculated from the monitored fluctuations of the corresponding reactant or product atom with
Eq. (11) or Eq. (12). In the scheme in Figure 1, the states with Einstein crystals are states 1b, 2b,
3b, and 4b.
2.3 Modified Hydrogen Atoms
The frequency of atom vibration depends on its mass. Hydrogen atoms generally have the highest
vibration frequencies in the system. Such high frequencies require short time step in MD simula-
tion and increase computational load. To limit vibration frequencies and allow a longer time step,
one can apply the SHAKE algorithm to fix the length of any bond involving hydrogen atoms.33
The SHAKE algorithm decreases the degrees of freedom in the system by introducing additional
constraints between atoms. Instead, we artificially changed the mass of hydrogen atoms from 1.008
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to 16.000 amu in order to preserve degree of freedom in the system following the suggestion by
Bennett.34 A larger mass of hydrogen atoms allows a longer time step in the MD algorithm. Pomes
and McCammon showed that changing the hydrogen mass to 10 amu allow using a 0.01 ps time
step to simulate a system which consists of 215 TIP3P water molecules, smaller than our system.35
Feenstra et al. change the mass of hydrogen atoms to 4 amu to increase the simulation stability of
a system which contains protein and water molecules and resembles our system.36 We set the time
step as 0.001 ps, a value widely used in simulations with physical masses for all atoms, to gain
higher stability in the simulation of our large system with a hemagglutinin trimer, a Fab dimer, and
water molecules. As with the Einstein crystals, we exactly calculated and subtracted off the con-
tribution of the change to the hydrogen mass to ∆∆G. Note that the modification of hydrogen mass
is independent to the reference states in the simulation, which is selected to be Einstein crystals
in this project. In fact, most of the hydrogen atoms in the system are neither reactant nor product
atoms. In Figure 1, the states with Einstein crystals and modified hydrogen atoms are states 1a, 2a,
3a, 4a, 1b, 2b, 3b, and 4b.
2.4 Expressions of Free Energies
Introducing two Einstein crystals and heavier hydrogen atoms changes the potential energy in the
system, as well as the canonical partition functions. After modification of hydrogen atoms, the
mass of atoms changed from mr,i to m′r,i, from mp,i to m′p,i, or from mx,i to m′x,i. Canonical partition
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functions of the states in Figure 1 are:
Q3 (n0 +n1,V,T ) = 1h3(n0+n1)
n0∏
i=1
(
2pimx,i
β
)3/2 n1∏
i=1
(
2pimr,i
β
)3/2
×Z3 (n0 +n1,V,T ) (13)
Q3a (n0 +n1,V,T ) = 1h3(n0+n1)
n0∏
i=1
(
2pim′x,i
β
)3/2
n1∏
i=1
(
2pim′r,i
β
)3/2
×Z3 (n0 +n1,V,T ) (14)
Q3b (n0 +n1 +n2,V,T ) = 1h3(n0+n1)
n0∏
i=1
(
2pim′x,i
β
)3/2
n1∏
i=1
(
2pim′r,i
β
)3/2
×Z3 (n0 +n1,V,T )
(
2pi
hβ
)3n2 n2∏
i=1
(
m′p,i
Kprodi
)3/2
(15)
Q4 (n0 +n2,V,T ) = 1h3(n0+n2)
n0∏
i=1
(
2pimx,i
β
)3/2 n2∏
i=1
(
2pimp,i
β
)3/2
×Z4 (n0 +n2,V,T ) (16)
Q4a (n0 +n2,V,T ) = 1h3(n0+n2)
n0∏
i=1
(
2pim′x,i
β
)3/2
n2∏
i=1
(
2pim′p,i
β
)3/2
×Z4 (n0 +n2,V,T ) (17)
Q4b (n0 +n1 +n2,V,T ) = 1h3(n0+n2)
n0∏
i=1
(
2pim′x,i
β
)3/2
n2∏
i=1
(
2pim′p,i
β
)3/2
×Z4 (n0 +n2,V,T )
(
2pi
hβ
)3n1 n1∏
i=1
(
m′r,i
Kreaci
)3/2
(18)
in which the states are denoted by the subscripts. Contribution of the potential energy part of the
Hamiltonian to the partition function is
Z3 (n0 +n1,V,T ) =
∫
exp(−βUn0+n1 (r))dr (19)
Z4 (n0 +n2,V,T ) =
∫
exp(−βUn0+n2 (r))dr (20)
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From the partition functions, free energies defined in Figure 1 are calculated:
∆G3a = −
3
2β
n0∑
i=1
ln
(
m′x,i
mx,i
)
−
3
2β
n1∑
i=1
ln
(
m′r,i
mr,i
)
(21)
∆G4a =
3
2β
n0∑
i=1
ln
(
m′x,i
mx,i
)
+
3
2β
n2∑
i=1
ln
(
m′p,i
mp,i
)
(22)
∆G3b = −
3n2
β ln
(
2pi
hβ
)
−
3
2β
n2∑
i=1
ln
(
m′p,i
Kprodi
)
(23)
∆G4b =
3n1
β ln
(
2pi
hβ
)
+
3
2β
n1∑
i=1
ln
(
m′r,i
Kreaci
)
(24)
∆G43b = −
1
β ln

 ∏
n1
i=1
(
m′r,i/Kreaci
)3/2
Z4 (n0 +n2,V,T )
∏n2i=1
(
m′p,i/K
prod
i
)3/2
Z3 (n0 +n1,V,T )

 . (25)
The free energy between state 3 and 4 is
∆G43 = ∆G43b−
1
β ln
(2pi/hβ )3n2 ∑n2i=1
(
mp,i/Kprodi
)3/2
(2pi/hβ )3n1 ∑n1i=1
(
mr,i/Kreaci
)3/2 = ∆G43b− 1β ln QE2 (n2,V,T )QE1 (n1,V,T ) (26)
in which QE1 and QE2 are the partition functions of the Einstein crystals for product atoms and
reactant atoms, respectively. The free energy ∆G43b was calculated by thermodynamic integration
while ∆G43 was used to calculate the free energy difference of one substitution. Note that the cor-
rection term between ∆G43b and ∆G43 is independent of the masses of atoms. Canonical partition
functions as well as free energies of the state 1, 1a, 1b, 2, 2a, and 2b are calculated in a similar
way.
2.5 Implementation of Free Energy Calculation Algorithm
The above discussion is the theoretical basis for the implementation of our free energy calculation
algorithm. The free energy calculation protocol consists of four steps. First, we built the dual
topology with reactant and product atoms in the amino acid substitution site in separated antibody
and hemagglutinin or antibody-hemagglutinin complex. We then solvated the protein system and
14
modified the mass of hydrogen atoms. Second, two Einstein crystals were introduced as the ref-
erence states for the reactant and product atoms, respectively. Third, the MD simulation was run
at 64 windows. The thermodynamic integration algorithm obtained the free energy values ∆G21
for separated antibody and hemagglutinin or ∆G43 for antibody-hemagglutinin complex, as in Fig-
ure 1. This step gave the ∆∆G value. Fourth, we calculated the error bar of the ∆∆G value obtained
in the last step. The technical details of these four steps are illustrated in the text below. Also
described are the verification of the free energy calculation protocol, the software and hardware
information, and the CPU hours consumed by the protocol.
The hemagglutinin trimer of H3N2 virus strain A/Aichi/2/1968 with bound dimer antibody
HC63 (PDB code: 1KEN) was used in our calculation. For each amino acid substitution, we
built the dual topology with side chains of both amino acids prior to the simulation. Reactant
and product atoms were defined as the side chains in the original and substituting amino acid,
respectively. All the covalent and non-bonded interactions between reactant and product atoms
were removed. The protein was in an explicit water box with periodic boundary condition. The
mass of hydrogen atoms was changed from 1.008 to 16.000 amu.
All the simulations were performed by CHARMM c33b2 with CHARMM22 force field.10
We first fixed the positions of hemagglutinin trimer except reactant atoms and minimized the sys-
tem with 200 steps of steepest descent (SD) algorithm and 5000 steps of adopted basis Newton-
Raphson (ABNR) algorithm. We ran a 5 ps MD simulation of the system, the trajectory of which
gave the spatial fluctuation
〈
(δ ri)2
〉
of each reactant atom. Then we fixed reactant atoms, released
product atoms, and ran a 5 ps MD simulation to obtain the spatial fluctuation of each product atom.
Final positions of both reactant and product were adopted as the reference positions of the corre-
sponding Einstein crystal. The force constant Ki of each atom in Einstein crystals was obtained
from
〈
(δ ri)2
〉
by Eq. (11) and Eq. (12). With modified hydrogen atoms and two Einstein crystals
as the reference states of reactant and product atoms, state 1b, 2b, 3b, and 4b in Figure 1 were
generated for thermodynamic integration.
In thermodynamic integration, MD simulations were run at 64 windows with distinct λ . In each
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window, pressure of the system was first calibrated with a 10 ps MD simulation in an isothermal-
isobaric (NPT) ensemble. The duration of 10 ps is appropriate because it is long enough to equi-
librate the pressure and short enough to prevent the protein from drifting away from the original
location. We fixed coordinates of the residues and water molecules except for those within 15 Å
from the three alpha carbons. Then we removed amino acid residues and water molecules other
than those within 27.5 Å from the three alpha carbons of substituted residues in the hemagglutinin
trimer to reduce the system size, because the fixed atoms are not included in the topology of mov-
able atoms and the cutoff of the non-bonded forces is 12 Å. The Ewald sum was used to calculate
charge interactions. Note that this substantial reduction of the system relies on the assumption
that the free energy change due to the amino acid substitution is mostly affected by atoms near the
binding site after the system reaches equilibrium. This assumption is based on two facts: the con-
formations of hemagglutinin and antibody are stable once the system reaches equilibrium, and all
the removed or fixed atoms have invariant interactions with the substituting amino acid residues.
The stable protein conformation means amino acid residues far away from the substituting residue
do not move during the amino acid substitution process. In the CHARMM22 force field used in
this project, the cutoff of non-bonded force is 12 Å and less than the 15 Å threshold for system
reduction. The system reduction does not directly affect the force on the substituted residue be-
cause of absence of the long-range non-bonded force between the substituted residue and atoms
removed from the system. This system reduction method was also applied to compute binding free
energy of subtilisin,37 of tripsin,21 and of Src SH2 domain.22 Robust results were obtained in all
of these applications. Generally, this system reduction strategy can produce reliable result if the
reduced system contains the residues and molecules critical to the binding process.21 We note that
the system reduction method could be a limitation of the free energy calculation model. The fixing
of amino acid residues and water molecules described in section 2.5 substantially reduced the CPU
time needed, but is an approximation to the real system containing the whole proteins. This lim-
itation reflects the tradeoff between model accuracy and required computational resource. In the
canonical ensemble, the new system was equilibrated for 200 ps and simulated for another 900 ps
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as the data production phase. The integrand of thermodynamic integration is the ensemble average
of the sampled trajectory 〈∂U (r,λ )/∂λ 〉λ =
〈
Uein,reac (r)−Ureac (r)−Uein,prod (r)+Uprod (r)
〉
λ .
The free energy ∆G21 and ∆G43 between the real states was calculated by adding a correction
term of the Einstein crystals in Eq. (26). Finally, the difference of antibody binding free energy is
∆∆G = ∆G43−∆G21.
Error bars of ∆∆G are also given. The convergence behavior of the simulation was analyzed
using the block average method developed by Flyvbjerg and Petersen.38 As mentioned above, the
MD simulation for either the unbound hemagglutinin or the hemagglutinin-antibody complex con-
tains 64 windows with distinct λ . The 900 ps data production phase contains 9×105 simulation
steps. The values A =Uprod (r)−Ureac (r), as in equation Eq. (3), computed in consecutive simula-
tion steps were grouped into bins, and consecutive bins were merged progressively. The quantity
σ 2 (A)/(n−1), in which σ 2 (A) is the variance of the average of each bin A1,A2, . . . ,An and n is
the number of bins, increases with the bin size and reaches a plateau when the bin size is 1×104
steps. We fixed the bin size to 1×104 steps and estimate the variance of ensemble average 〈A〉 as
σ 2 (A)/(n−1), following Flyvbjerg and Petersen’s method.38
This protocol, without the Einstein crystal contribution, was verified by recalculating published
free energy differences of amino acid substitution T131I.9 Without the Einstein crystal contribu-
tion, our protocol gave the ∆∆G = 5.69± 0.07 kcal/mol, compared to the ∆∆G = 5.20± 0.94
kcal/mol in the published work.9 Theoretically exact results presented here include the Einstein
crystal contribution. We note that the theoretically exact ∆∆G for T131I, including the Einstein
crystal contribution, is 3.71±0.07 kcal/mol.
The simulation was performed using CHARMM22 force field at three clusters: tg-steele.purdue.teragrid.org
(Intel Xeon E5410, 2.33 GHz), sugar.rice.edu (Intel Xeon E5440, 2.83 GHz), and biou.rice.edu
(IBM POWER7, 3.55 GHz), as well as at the condor pool tg-condor.rcac.purdue.edu at Purdue
University. Simulation of each substitution took approximately 7.5 thousand CPU hours on aver-
age, and so this work consumed about three million CPU hours.
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3 Results
3.1 Free Energy Landscape
For each of the 21 amino acid sites in epitope B, we substituted from alanine to each one of the
19 other amino acids, in which we used the neutral histidine (CHARMM code: Hse) as the model
of histidine. The free energy difference and standard error of each substitution were calculated by
the MD simulation (see Materials and Methods). The wildtype amino acid in each site of epitope
B was extracted from the hemagglutinin sequence of the H3N2 strain A/Aichi/2/1968. The free
energy difference and standard error of the substitution from the wildtype amino acid in each site
were then calculated from the values for the change from the wildtype amino acid to alanine and
from alanine to the new amino acid. The values are listed in Table 1.
As described in Eq. (26), each ∆∆G value listed in Table 1 contains the contribution of two
Einstein crystals. The contribution of Einstein crystals to the final ∆∆G values was calculated for
each of the 399 amino acid substitutions in epitope B. The average fraction of the contribution of
Einstein crystals in the calculated ∆∆G values is 44%. The contribution of Einstein crystals is far
greater than that of the statistical error of our free energy calculation in Table 1, which is 4.5% on
average. Thus, the Einstein crystal contribution is both theoretically exact and practically impor-
tant. In 371 of the 399 substitutions, the absolute values of the contribution of Einstein crystals
is greater than 1.96 standard errors of the final ∆∆G values. That is, the contribution of Einstein
crystals is significant with p < 0.05 in 93.0% of all the amino acid substitutions. Consequently,
it is essential to incorporate Einstein crystals in the free energy calculation to eliminate the error
caused by the methods that neglect the unknown effect of the translational entropy of the free
atoms in thermodynamic integration. The contribution of the translational entropy of ideal gas-like
atoms (λ = 0 or λ = 1) needs to be either calculated or removed by a theoretically exact method
to perform an exact free energy calculation.
The obtained ∆∆G values allow us to analyze the character of each of the 20 amino acids.
We first averaged over all the 21 amino acid sites in epitope B the ∆∆G value caused by the
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Table 1: Summary of the calculated free energy differences ∆∆G in each amino acid site in epitope
B from the wildtype amino acid to all 20 amino acids. The standard errors are also listed. The free
energy difference and its standard error of the substitution from the wildtype amino acid to itself
are both zero. The units of free energy differences and their standard errors are kcal/mol.
Positions 128 129 155 156 157 158 159
Ala −13.12±0.27 3.33±0.29 2.78±0.20 1.19±0.33 2.48±0.21 4.27±0.31 5.18±0.21
Arg 22.57±0.46 2.31±0.45 16.98±0.37 0.08±0.50 −4.19±0.44 −1.61±0.48 7.07±0.42
Asn −4.80±0.36 5.83±0.42 −7.83±0.30 10.72±0.40 5.64±0.34 3.41±0.42 10.97±0.35
Asp 4.52±0.38 19.12±0.42 16.28±0.32 11.06±0.42 9.95±0.37 18.37±0.40 15.34±0.36
Cys −11.83±0.34 12.64±0.37 −2.37±0.30 5.32±0.38 −2.72±0.29 −7.88±0.40 7.92±0.32
Gln −12.37±0.40 7.34±0.42 −4.29±0.36 13.14±0.41 −0.45±0.36 11.47±0.43 6.54±0.40
Glu 11.15±0.38 10.50±0.42 17.77±0.34 26.54±0.43 4.68±0.36 8.58±0.48 5.19±0.39
Gly −9.93±0.39 0.00±0.00 17.00±0.34 0.11±0.44 0.21±0.36 0.00±0.00 −4.19±0.41
Hse 4.43±0.42 0.15±0.43 2.47±0.36 −6.89±0.43 12.18±0.38 5.54±0.46 1.06±0.39
Ile −16.03±0.41 0.54±0.40 1.55±0.33 8.33±0.42 11.22±0.37 8.09±0.43 18.96±0.39
Leu −23.58±0.41 −4.27±0.43 −8.92±0.33 2.64±0.45 −6.26±0.39 1.61±0.45 4.08±0.38
Lys 3.57±0.45 11.18±0.46 14.58±0.37 0.00±0.00 6.24±0.40 −1.60±0.48 5.39±0.46
Met −13.38±0.39 −2.59±0.39 1.23±0.35 10.11±0.43 16.15±0.36 14.49±0.44 −6.38±0.37
Phe −10.21±0.45 6.12±0.43 9.39±0.35 0.30±0.45 10.28±0.40 5.17±0.48 12.33±0.42
Pro −9.36±0.36 −2.43±0.42 −1.86±0.31 2.32±0.43 5.69±0.30 17.09±0.40 6.08±0.36
Ser −14.55±0.34 3.36±0.37 −1.09±0.29 −1.45±0.38 0.00±0.00 2.76±0.39 0.00±0.00
Thr 0.00±0.00 7.35±0.36 0.00±0.00 −1.08±0.41 6.34±0.32 8.36±0.41 15.32±0.32
Trp 9.82±0.47 4.81±0.47 19.84±0.43 23.26±0.48 16.14±0.45 3.52±0.62 −1.35±0.45
Tyr −14.83±0.43 2.72±0.42 7.25±0.36 −2.18±0.46 −8.37±0.44 18.42±0.51 5.95±0.43
Val −19.13±0.37 3.56±0.38 8.57±0.31 −3.01±0.39 7.63±0.32 3.77±0.42 6.45±0.32
Positions 160 163 165 186 187 188 189
Ala 4.16±0.22 −0.24±0.22 4.15±0.24 −3.19±0.19 −4.03±0.23 3.45±0.25 −9.01±0.28
Arg 9.70±0.44 5.97±0.39 14.58±0.41 21.01±0.38 8.12±0.42 −0.06±0.45 −0.39±0.48
Asn 2.07±0.34 −2.32±0.32 0.00±0.00 4.67±0.30 −10.07±0.34 0.00±0.00 −3.18±0.37
Asp 13.50±0.32 12.64±0.32 25.01±0.31 24.54±0.28 7.78±0.35 19.77±0.37 6.77±0.35
Cys 15.82±0.31 1.84±0.30 1.93±0.29 −2.30±0.25 −11.09±0.32 4.07±0.34 6.23±0.33
Gln 3.04±0.39 −8.29±0.35 4.27±0.36 5.16±0.33 −2.87±0.37 12.36±0.39 0.00±0.00
Glu 15.48±0.36 2.17±0.35 15.74±0.34 33.29±0.31 14.41±0.35 10.10±0.37 12.16±0.39
Gly 1.22±0.39 −5.83±0.38 9.11±0.37 0.13±0.27 −0.60±0.30 −5.06±0.32 −5.69±0.32
Hse 0.52±0.38 6.31±0.33 7.44±0.33 18.15±0.30 3.69±0.39 −1.95±0.40 −8.53±0.40
Ile 1.51±0.34 10.62±0.36 3.85±0.33 −1.85±0.30 −2.51±0.33 −4.77±0.37 3.65±0.37
Leu −1.39±0.40 3.85±0.35 −9.20±0.37 1.07±0.30 −0.40±0.38 −1.30±0.37 −6.91±0.39
Lys 5.91±0.44 10.37±0.38 1.93±0.41 −1.15±0.39 24.91±0.41 8.42±0.44 9.48±0.64
Met 10.78±0.38 7.22±0.35 1.63±0.36 13.06±0.33 −5.11±0.36 6.97±0.38 6.86±0.40
Phe 7.90±0.41 −0.86±0.36 13.87±0.38 6.94±0.33 −7.23±0.39 2.05±0.39 4.37±0.43
Pro 4.51±0.32 12.50±0.34 18.96±0.33 11.82±0.29 10.69±0.32 −10.24±0.35 −8.98±0.36
Ser 7.13±0.29 9.07±0.30 −0.92±0.28 0.00±0.00 −4.88±0.31 8.09±0.33 −5.09±0.34
Thr 0.00±0.00 9.18±0.30 10.35±0.31 −14.79±0.27 0.00±0.00 3.53±0.38 9.30±0.35
Trp 0.86±0.44 12.34±0.35 19.02±0.43 −7.69±0.38 −11.04±0.48 7.20±0.40 −9.19±0.45
Tyr −5.43±0.39 1.06±0.34 14.76±0.37 11.90±0.33 5.29±0.42 1.57±0.40 4.81±0.41
Val 7.99±0.34 0.00±0.00 9.79±0.32 2.97±0.29 3.08±0.33 3.73±0.34 −7.89±0.36
Positions 190 192 193 194 196 197 198
Ala −18.12±0.24 −0.86±0.23 −5.20±0.20 2.37±0.23 5.95±0.23 −2.40±0.29 0.00±0.00
Arg 4.97±0.41 23.07±0.44 32.33±0.41 −13.66±0.37 −25.38±0.44 −17.94±0.47 3.99±0.37
Asn −16.44±0.30 −2.56±0.32 8.24±0.30 −3.81±0.31 13.27±0.36 −6.58±0.38 0.05±0.28
Asp 18.75±0.32 2.92±0.32 15.29±0.29 26.72±0.35 9.25±0.34 5.58±0.39 5.17±0.24
Cys −20.36±0.32 −1.45±0.32 −9.79±0.26 1.91±0.30 1.30±0.31 6.70±0.36 5.91±0.22
Gln −17.37±0.37 −6.00±0.37 4.87±0.34 −0.83±0.32 7.68±0.36 0.00±0.00 1.41±0.31
Glu 0.00±0.00 1.18±0.35 45.40±0.34 38.35±0.33 3.60±0.36 11.34±0.41 2.37±0.30
Gly −17.09±0.29 −13.46±0.30 −13.89±0.27 −18.59±0.30 8.08±0.31 4.11±0.36 3.65±0.28
Hse −26.26±0.35 −0.96±0.38 −0.96±0.35 9.95±0.34 18.42±0.37 −2.62±0.40 −3.27±0.35
Ile −16.45±0.37 −5.57±0.37 −3.80±0.31 −6.91±0.32 0.77±0.34 1.23±0.41 0.01±0.32
Leu −17.27±0.36 −7.97±0.37 10.76±0.34 0.00±0.00 10.07±0.39 −0.03±0.40 −11.18±0.29
Lys −9.33±0.38 5.67±0.42 39.36±0.39 −16.67±0.38 0.49±0.40 −16.50±0.47 1.98±0.37
Met −26.63±0.34 6.82±0.36 −2.91±0.32 7.75±0.35 4.08±0.37 −7.79±0.40 15.57±0.32
Phe −31.89±0.39 1.56±0.40 16.46±0.59 2.78±0.34 −1.99±0.37 1.05±0.44 8.73±0.34
Pro −17.85±0.33 −2.28±0.33 9.84±0.31 8.01±0.31 15.42±0.35 −5.34±0.40 0.70±0.29
Ser −14.75±0.31 −7.79±0.30 0.00±0.00 6.62±0.29 6.91±0.29 1.97±0.36 −2.40±0.22
Thr −4.17±0.32 0.00±0.00 −2.04±0.27 12.40±0.31 7.81±0.33 −7.91±0.36 6.79±0.24
Trp −22.93±0.39 2.31±0.44 17.92±0.42 −1.30±0.40 8.17±0.43 −7.73±0.44 −7.23±0.38
Tyr −13.82±0.38 7.63±0.42 16.16±0.38 9.73±0.36 2.92±0.40 6.10±0.44 −4.82±0.32
Val −9.12±0.31 −6.80±0.32 −6.92±0.30 2.59±0.29 0.00±0.00 4.16±0.39 −4.22±0.24
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single substitutions from alanine to the other amino acids. The averaged ∆∆G values are listed in
Table 2. The largest ∆∆G are caused by the negatively charged amino acids (Glu, Asp) and the
positively charged amino acids (Arg, Lys), indicating that introduction of charged amino acids in
the dominant epitope decreases the binding affinity between antibody and hemagglutinin. Note that
amino acid substitutions that change the charge of hemagglutinin significantly affect the calculated
free energy values.39–41 The issue of how to best calculate free energy differences when charge
changes has been debated over the years. In the present paper, we are using the standard Ewald
approach with explicit solvent. We note that the evolutionary history of H3 hemagglutinin since
1968 shows an increasing trend of the number of charged amino acids in epitope B,42 which
agrees with the results that introduction of charged amino facilitates virus evasion from antibody,
as illustrated in Table 2. The result that introduction of charged amino acid on average increases
∆∆G is not an artifact, is supported by data from the influenza evolution, and is expected on the
basis that charge is hydrophilic. In addition to the charge, the rank of free energy differences also
largely correlated to the size of amino acid. By the definition used by RasMol,43 the 16 uncharged
amino acids are tagged as hydrophobic (Ala, Gly, Ile, Leu, Met, Phe, Pro, Trp, Tyr, Val), large (Gln,
Hse, Ile, Leu, Met, Phe, Trp, Tyr), medium (Asn, Cys, Pro, Thr, Val), and small (Ala, Gly, Ser),
as shown in Table 2. The ranks of small amino acids are lower than those of medium amino acids
(p = 0.036, Wilcoxon rank-sum test) and those of large amino acids (p = 0.085, Wilcoxon rank-
sum test). In contrast, the hydrophobicity of the uncharged amino acids is largely uncorrelated to
their ranks by ∆∆G. As a result, charged amino acids in the dominant epitope are essential to the
immune evasion while the virus escape substitution among small amino acids have minimal effect.
Epitope B comprises 21 amino acid sites in the top of the hemagglutinin trimer. Taking the
probability for one substituting amino acid to exist at each site to be proportional to the relative
frequency of this amino acid in H3 hemagglutinin, the weighted average free energy difference in
each of the 21 sites was calculated. The relative frequencies of 20 amino acids were obtained from
6896 H3 hemagglutinin sequences deposited between 1968 and 2009 in the NCBI database44 and
listed in Table 2. Also using the ∆∆G values in Table 1, we calculated and tabulated in Table 3
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Table 2: The rank of the average binding free energy difference of the single substitution from
alanine to another amino acid over all the 21 amino acid sites in epitope B of hemagglutinin trimer.
The rank correlates with the charge and the size of amino acid, and it is relatively uncorrelated
to the hydrophobicity. Here we applied classifications of RasMol for the biochemical properties
of the 20 amino acids.43 The relative frequencies of 20 amino acids were counted from the H3
sequences in NCBI database from 1968 to 2009.
Rank Amino Acid ∆∆G (kcal/mol) Charged Hydrophobic Large Medium Small Relative frequency
1 Glu 14.612±0.061 × × 0.029
2 Asp 14.533±0.055 × × 0.051
3 Arg 6.018±0.078 × × 0.052
4 Lys 5.766±0.078 × × 0.057
5 Trp 4.458±0.081 × × 0.016
6 Tyr 3.984±0.071 × × 0.035
7 Thr 3.981±0.050 × 0.078
8 Pro 3.912±0.054 × × 0.060
9 Met 3.562±0.062 × × 0.009
10 Phe 3.522±0.073 × × 0.030
11 Hse 2.654±0.064 × 0.020
12 Gln 1.985±0.063 × 0.042
13 Ile 1.396±0.060 × × 0.070
14 Asn 1.150±0.054 × 0.085
15 Val 1.147±0.051 × × 0.055
16 Cys 0.888±0.046 × 0.028
17 Ser 0.469±0.044 × 0.096
(18) (Ala) (0.000±0.000) × × 0.046
19 Gly −1.612±0.055 × × 0.070
20 Leu −2.273±0.064 × × 0.071
for each site i the value of 〈∆∆G〉i, which is the average ∆∆G weighted by the probability for each
different amino acid to be introduced, where probability is proportional to the relative frequencies
of 20 amino acids counted from the H3 sequences in NCBI database from 1968 to 2009.
As shown in Table 3, there is obvious variation among the expected free energy differences
〈∆∆G〉i caused by single substitutions at amino acid site i of epitope B. This variation is partly due
to the wildtype amino acids in the sites. For instance, the wildtype amino acid in site 190 is Glu that
has the highest rank in Table 2. As shown in Table 3, any amino acid substitution in site 190 tends
to have a negative ∆∆G. Another cause of variation in 〈∆∆G〉i is that distinct sites affect differently
the antibody binding process. Epitope B of the wildtype A/Aichi/2/1968 hemagglutinin sequence
contains five sites with threonine: 128, 155, 160, 187, and 192. The mathematical expectancies
〈∆∆G〉i in these five sites are −7.746, 4.471, 4.956, 1.182, and −1.737 kcal/mol, respectively.
Therefore, each site in epitope B has a specific effect on the virus escape substitution. A random
substitution in epitope B affects the antibody binding free energy differently depending on the site
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Table 3: The rank of the average free energy difference 〈∆∆G〉i generated by a substitution in each
amino acid site i of epitope B.
Rank Site 〈∆∆G〉i (kcal/mol)
1 193 8.074±0.081
2 159 7.792±0.094
3 165 7.741±0.086
4 158 6.128±0.108
5 196 5.444±0.088
6 160 4.956±0.090
7 186 4.754±0.076
8 163 4.722±0.085
9 129 4.690±0.103
10 155 4.471±0.081
11 156 4.029±0.106
12 157 3.944±0.090
13 188 2.945±0.092
14 194 1.886±0.080
15 187 1.182±0.087
16 198 0.531±0.072
17 189 −0.631±0.098
18 192 −1.737±0.087
19 197 −1.967±0.099
20 128 −7.746±0.098
21 190 −12.666±0.084
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and the substituting amino acids.
The variation of 〈∆∆G〉i is also reflected by the tertiary structure of the epitope B bound by
the antibody. By looking into the structure of epitope B shown in Figure 2. Epitope B resides
in two protruding loops from amino acid site 128 to 129, and from site 155 to 165, respectively,
and in a α-helix from site 186 to 198. Site 128 has a negative average free energy difference
〈∆∆G〉128 = −7.746± 0.098 kcal/mol. All the other sites in these two loops show a positive
〈∆∆G〉i value of a random substitution, with the minimum 〈∆∆G〉157 = 3.944±0.090 kcal/mol in
site 157. The α-helix is located between hemagglutinin and antibody. In the α-helix, the sites
facing towards the antibody usually present large positive 〈∆∆G〉i values such as site 193 and 196,
while the sites facing towards the hemagglutinin show lower 〈∆∆G〉i such as site 189, 192, and
197. Thus in the one dimensional sequence from site 186 to 198, the 〈∆∆G〉i values oscillate with
peaks and valleys corresponding to the sites in the α-helix facing alternatingly to the antibody and
hemagglutinin. Consequently, the variation of the expected free energy changes in distinct sites
depends on the structure of the hemagglutinin-antibody complex.
3.2 Historical Substitutions in Epitope B
The simulation results are supported in two aspects by amino acid sequence data of H3 hemagglu-
tinin collected since 1968. These historical sequences are downloaded from the NCBI Influenza
Virus Resource45 and aligned. First, Pan et al. analyzed the number of charged amino acid in
epitope B of H3 hemagglutinin in each year since 1968, and found an increasing trend of charged
amino acids.42 This finding supports the results that amino acid substitution introducing charged
residues on average facilitates virus escape from antibody, as illustrated in Table 2. Second, amino
acid substitutions in epitope B between 1968 and 1975 also verified the free energy calculation, as
shown below.
With the knowledge of the free energy landscape of the single substitutions, we are able to rec-
ognize favorable single substitutions in epitope B. Substitutions with large positive ∆∆G values en-
able the virus to evade the immune pressure and increase the virus fitness. Favorable substitutions
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Figure 2: The tertiary structure of the interface between the HA1 domain of H3 hemagglutinin
monomer A/Aichi/2/1968 (bottom) and the antibody HC63 (top) (PDB code: 1KEN). Water
molecules are not shown. Epitope B of the HA1 domain is located in two loops and one α-helix
with the color scale modulated according to the expected free energy difference 〈∆∆G〉i of each
site i in epitope B. The color scale ranges from red for the most negative 〈∆∆G〉i values to blue for
the most positive 〈∆∆G〉i values. The sites i in epitope B with 〈∆∆G〉i near zero are colored white.
The region outside epitope B is colored gray. The red site 128 is far from the antibody binding
region and the red site 190 possessed the original amino acid Glu, which is a charged amino acid.
It may explain why these two sites show negative 〈∆∆G〉i with large absolute values.
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grow in the virus population. Selection for substitutions with large ∆∆G is part of the evolutionary
strategy of the virus. The results of free energy calculation can also explain the substituted virus
strains collected in history.
We analyzed the hemagglutinin sequence information of H3N2 strains evolving from the A/Aichi/2/1968
strains. H3 hemagglutinin circulating from 1968 to 1971 was mainly in the HK68 antigenic cluster
while those circulating from 1972 to 1975 were mainly in the EN72 antigenic cluster.46 Table 4
shows that in the dominant epitope B, there were 17 substitutions occurred in 12 sites collected be-
tween 1968 to 1975,47 which contributed to the immune evasion and corresponding virus evolution
from the HK68 cluster to the EN72 cluster. Also listed in Table 4 are the free energy differences of
these historical substitutions. The 17 substituting amino acids have significantly higher ranks com-
pared to the corresponding wildtype amino acids (p = 0.0044, Wilcoxon signed-rank test). This
significant difference is expected because 15 of 17 substituting amino acids have ranks between
1 and 10, while 10 of 12 wildtype amino acids in the substituted site have ranks between 11 and
20. In all the 21 sites in epitope B, 15 of 21 wildtype amino acids have ranks between 11 and
20. Additionally, the ∆∆G values of these 17 substitutions listed in Table 4 are greater than the
expected free energy differences 〈∆∆G〉i in Table 3 of random substitutions in the 12 substituted
sites (p = 0.013, Wilcoxon signed-rank test).
We also looked into the historical escape substitutions in epitope B evading the immune pres-
sure of the vaccine strains. For each influenza season, the amino acids in the administered vaccine
strain were defined as the wildtype ones and those in the dominant circulating strain as the sub-
stituting amino acids. In each of the 19 seasons in which H3N2 virus was the dominant subtype
from 1971 to 2004, the substitutions in epitope B were located3 and their ∆∆G values were ob-
tained from Table 1. As shown in Table 5, escape substitutions in epitope B as of 1973 mostly had
positive ∆∆G and generated substituting amino acids with increased rank (p = 0.047, Wilcoxon
signed-rank test). Such tendency to introduce amino acids with higher ranks was not observed
after 1973: the ranks of wildtype and substituting amino acids after 1973 present little significant
difference (p = 0.28, Wilcoxon signed-rank test). The hemagglutinin of A/Aichi/2/1968 used in
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Table 4: Substitutions occurred in epitope B of the hemagglutinin A/Aichi/2/1968 (H3N2) as of
1975. Also listed are the time when the substitutions were observed, and the free energy differences
with standard errors. In each site of epitope B, all the 20 amino acid were sorted in the descending
order by the free energy differences introduced by a substitution from the wildtype amino acid to
20 amino acids. The ranks of the substituting amino acid and the wildtype amino acid in each
substituted site are listed in the column Rank (substituting) and Rank (WT), respectively.
Substitution Year ∆∆G (kcal/mol) Rank (substituting) Rank (WT)
T128N 1971 −4.796±0.361 8 7
T128I 1975 −16.026±0.412 18 7
G129E 1970, 1972 10.500±0.415 4 17
T155Y 1972–1973, fixed in 1973 7.254±0.358 9 14
G158E 1971–1972 8.584±0.479 6 17
S159N 1971, 1974–1975 10.969±0.352 5 17
S159C 1972 7.923±0.324 6 17
S159R 1972 7.065±0.424 7 17
T160A 1973 4.160±0.217 11 18
S186N 1975 4.673±0.298 10 14
N188D 1971–1973, fixed in 1973 19.767±0.367 1 14
Q189K 1975 9.484±0.640 2 10
E190V 1972 −9.115±0.310 5 3
E190D 1975 18.752±0.324 1 3
S193N 1972–1975 8.239±0.301 10 12
S193D 1975 15.285±0.294 7 12
A198T 1972 6.793±0.236 3 14
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the free energy calculating is in the HK68 antigenic cluster. Perhaps after the virus evolved into
the next EN72 cluster, change in the virus antigenic character stimulates the immune system to
produce new types of antibody other than the HC63 antibody used in the calculation. A different
binding antibody changes the free energy landscape of the substitutions in epitope B. Thus the
application of the present free energy landscape should be limited within the HK68 and EN72
clusters. Free energy differences of substitutions in the EN72 cluster would need to be calculated
using the updated antibody crystal structure.
4 Discussion
4.1 Fitness of the Virus Strains
The free energy landscape shown in Table 1 gives the change of the antibody binding affinity,
K1/K0 = exp(−∆∆G/RT ), induced by each possible substitution in epitope B of the wildtype
hemagglutinin. The majority of the substitutions lead to positive ∆∆G, and yield a reduced binding
affinity K1 that is smaller than the binding affinity of the original mature antibody K0. Decreased
antibody binding constant grants the virus a higher chance of evading the immune pressure and
infecting host cells. We propose that virus fitness is positively correlated to the free energy differ-
ence ∆∆G. The other factor affecting virus fitness is the capability of the hemagglutinin to maintain
the normal biochemical functions, such as virus entry. Most sites in epitope B changed amino acid
identities during 1968 to 2005 as the H3N2 virus kept circulating.47 We therefore postulate that the
substitutions in epitope B do not greatly interfere with the biochemical function of hemagglutinin,
and virus fitness is dominantly determined by the free energy difference resulted from substitutions
in epitope B.
The binding constant between hemagglutinin and antibody after the first round of maturation
is about 106 M−1, and the binding constant of an uncorrelated antibody is below 102 M−1.2 On
average, four substitutions in epitope B change the substituted hemagglutinin sufficiently so that
the immune response of the original antibody binding to epitope B is abrogated.3 Since this is a
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Table 5: Substitutions occurred in epitope B of H3 hemagglutinin between the vaccine strain and
the dominant circulating strain in each season in which the H3N2 subtype was dominant. The
free energy difference with standard error of each substitution is obtained using the free energy
landscape in Table 1. The ranks of free energy differences sorted in the descending order are listed
in column Rank (vaccine) and in column Rank (circulating) for the amino acids in the vaccine
strain and the dominant circulating strain, respectively.
Year Substitution ∆∆G (kcal/mol) Rank (vaccine) Rank (circulating)
1972 T155Y 7.254±0.358 14 9
1972 G158E 8.584±0.479 17 6
1972 S159C 7.923±0.324 17 6
1972 E190V −9.115±0.310 3 5
1973 T160A 4.160±0.217 18 11
1973 N188D 19.767±0.367 14 1
1973 S193N 8.239±0.301 12 10
1975 S157L −6.256±0.394 15 19
1975 A160T −4.160±0.217 11 18
1975 Q189K 9.484±0.640 10 2
1975 N193D 7.046±0.317 10 7
1984 E156K −26.536±0.429 1 15
1984 V163A −0.243±0.217 15 16
1984 D190E −18.752±0.324 1 3
1984 I196V −0.768±0.343 16 18
1987 Y155H −4.782±0.414 9 11
1987 E188D 9.669±0.382 3 1
1987 K189R −9.872±0.697 2 11
1996 V190D 27.867±0.299 5 1
1996 L194I −6.914±0.324 13 17
1997 K156Q 13.140±0.413 15 3
1997 E158K −10.187±0.515 6 18
1997 V190D 27.867±0.299 5 1
1997 L194I −6.914±0.324 13 17
1997 V196A 5.947±0.229 18 11
2003 H155T −2.472±0.355 11 14
2003 Q156H −20.028±0.365 3 20
2003 S186G 0.132±0.275 14 13
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reduction of the binding constant from roughly 106 M−1 to 102 M−1, one amino acid substitution
that contributes to immune escape causes on average a 10-fold decrease in antibody binding con-
stant, or equivalently ∆∆Gcrit = 1.42 kcal/mol at 310 K. Assuming the effect of immune evasion
can be broken into the sum of individual amino acid substitutions in the dominant epitope,3 we
define the virus fitness w as the sum of the contribution in each site of epitope B
w = A0 + ∑
epitope B
δwi. (27)
We denote by ∆∆Gαγi the free energy difference to substitute amino acid α to amino acid γ at site
i. We investigated two versions of the virus fitness landscape. The first is to define δwi as a linear
function of the free energy difference of the substitution
δwi = A1
∆∆Gαγi
∆∆Gcrit
. (28)
The second is to define δwi as a step function
δwi = A2H
(
∆∆Gαγi −∆∆Gcrit
) (29)
in which H is the Heaviside step function. Illustrated in the simulation below, either definition of
fitness is sufficient to explain the observed immune evasion of the H3N2 virus.
4.2 Selection in the Epitope
Evolution of the H3N2 virus is driven jointly by neutral evolution and selection.48 Neutral evolu-
tion may be ongoing in sites outside the epitopes. The high substitution rate in epitope B suggests
that selection is the major factor shaping the pattern of evolution in that epitope.47 Shown in Ta-
ble 4 and Table 5 are the historical substitutions. The significantly increased ranks of free energy
differences suggests the existence of selection by the immune pressure for substitutions that have
increased the free energy difference ∆∆G and decreased the antibody binding constant. The im-
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mune selection is directional: certain types of amino acids such as charged ones were initially
more likely to be added into the epitope B42 because they maximally decreased the antibody bind-
ing constant as indicated in Table 2. The heterogeneity of the expected free energy difference of a
random substitution in Table 3 shows that each site in epitope B has a specific weight with regard
to immune escape.
Table 4 also illustrates that the immune selection did not necessarily pick the amino acid with
the highest rank of ∆∆G as the substituting amino acid. Amino acids with moderate rank were
introduced into epitope B even for the fixed substitution T155Y. Therefore the historical evolution
did not simply substitute amino acids by maximizing the free energy differences in Table 1. This
phenomenon is possibly due to two causes. First, the virus fitness may be insensitive to the ∆∆G
values, e.g. A1 in Eq. (28) may be small, or amino acid substitutions with large ∆∆G values
may contribute equivalently to the fitness, as in Eq. (29). Second, only a small fraction of virus
in one host is shed by the host and infects the next host, so the population size of propagated
virus from one host is smaller by several orders of magnitude than the total virus population size
in the same host. Additionally, a seasonal bottleneck exists in the influenza virus circulation.49
Both random mutation and small population sizes lead to dramatic randomness in the evolution.
Consequently, the evolution of H3 hemagglutinin is not solely determined by maximizing the free
energy differences in Table 1 and minimizing the antibody binding constant, even if the virus is
under immune selection. Instead, randomness plays a key role in the H3N2 virus evolution.
4.3 A Picture of the H3N2 Virus Evolution
Selection depends on the fitness of each virus genotype that is quantified as a non-decreasing
function of the free energy difference ∆∆G. Moderate selection in epitope B requires that fitness
improvement is limited when ∆∆G is large. One possibility is that the ratio A1/A0 in Eq. (28)
is small. Another is that the fitness takes the form of Eq. (29) in which all substitutions with
∆∆G > ∆∆Gcrit have equal fitness.
The virus evolution is also affected by the genetic drift. Genetic drift is a term which captures
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the random component of evolution due to the large size of the phase space of possible substitutions
relative to the single set of substitutions that lead to the highest viral fitness. The effect of genetic
drift is quantitatively reflected in the fixation process of a new strain, as shown in the simulation
below. A narrow bottleneck of virus propagation allows only a small fraction of the progeny to
survive, imposing a notable probability that a favorable substitution is lost in the next generation.
The effect of genetic drift is to increase the randomness in the virus evolution so that observed
substitutions are based on chance in addition to the fitness of these substitutions.
To model the H3N2 evolution discussed above, we ran two Monte Carlo simulations of the
influenza evolution model. A population of N sequences of epitope B with 21 sites were created
and initialized as the wildtype A/Aichi/2/1968 sequence. Here N = 103 to account for a narrow
genetic bottleneck of hemagglutinin and for tractability of the simulation. We iterated the simula-
tion program for 5,000 generations or about five years to recreate a pattern of evolution similar to
that in history and shown in Table 4. The random substitution rate of H3 hemagglutinin is roughly
4.5×10−6 amino acid substitution/site/generation.50 We let the number of substitutions follow a
Poisson distribution with mean λ = 21×4.5×10−6N = 9.5×10−5N and randomly assigned the
substitution sites. The substituting amino acid at each substitution site was randomly picked from
the remaining 19 amino acids proportional to the historical frequencies observed in hemagglutinin.
The fitness w in the first simulation was calculated for each sequence using Eq. (28) with A0 = 100
and A1 = 3 and that in the second simulation was calculated for each sequence using Eq. (29)
with A0 = 100, A2 = 9, and ∆∆Gcrit = 1.42 kcal/mol. Note that by choosing A1 = 3 for the first
simulation, a random substitution causes the expected fitness to change from 100 to 104.9, and
by choosing A2 = 9 for the second simulation, a random substitution changes the expected fitness
from 100 to 105.0. The size of the progeny of each sequences equals the fitness w of the sequence
if w > 0, and equals 0 if w ≤ 0. The next generation of sequences was initialized by randomly
sampling N sequences from the progeny sequences.
The results of both simulations showed remarkable similarity to the observed substitutions in
Table 4 with the bottleneck N equal to 103. See Figure 3 and Figure 4. Amino acid substitutions
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generated in the simulation are usually distinct with those in Table 4 observed in history. The
∆∆G values of each substitution emerging in the simulation are nevertheless similar to those of
the historical substitutions listed in Table 4. As was observed in history in Table 4, most of the
substituted strains in the simulations with relative frequency greater than 1% have positive ∆∆G
values with the ranks of the substituting amino acids ranging from 1 to 10. The fixation of a newly
emerged substitution takes about 1,000 generations or one year on average. Fixed substitutions
mostly introduce amino acids with positive ∆∆G values in Table 1 and higher ranks in Table 2,
and several of these fixed substitutions in simulation, such as E190D and N188D, have the highest
∆∆G values in the current site. However, fixed substitutions in the simulation are not always
the substitutions with the highest ∆∆G values in Table 1. These observations suggest that the
Monte Carlo simulation considering the effect of substitution, selection, and genetic drift is able
to reproduce the pattern of evolution observed in history. This simulation also shows that besides
the free energy difference of each substitution, the mapping from the free energy landscape to the
fitness landscape as well as the random genetic drift are dominant factors of the evolution in virus
epitopes.
Shown in Figure 3 and Figure 4 for both simulations are the trajectories of relative frequencies
of substituting amino acids. The trajectories are similar to historical observations of human H3N2
virus data.47 For influenza, 1000 generations roughly equal one year. The two substitutions T155Y
and N188D were fixed in epitope B in 1968–1973. As indicated by Figure 3 and Figure 4, substitu-
tion T155Y emerged between generation 3000 and 4000, or equivalently between 1971 and 1972
from the emergence of the H3N2 virus in 1968.47 Substitution T155Y was fixed between gener-
ation 4000 and 5000. Similarly, substitution N188D emerged between generation 2000 and 3000
and was fixed between generation 4000 and 5000. The first simulation in which virus fitness is cal-
culated using Eq. (28) generated two fixed substitution, G129A that emerged at generation 4000
and was fixed by generation 5000, and E190D that emerged at generation 3600 and was fixed by
generation 3900. The second simulation using Eq. (29) generated one fixed substitutions, V196D
emerging at generation 2900 and fixed by generation 5000, and one substitution that nearly fixed,
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N188D emerging at generation 4100 and acquiring the relative frequency 0.84 at generation 5000.
The trajectories in both simulations resemble those of substitutions T155Y and N188D observed
in history. From these results, the two Monte Carlo simulations appear to capture the main factors
of immune selection and genetic drift in evolution of the H3N2 virus.
4.4 Multiple Substitutions
In this work, we calculated the free energy difference for each possible substitution in epitope B.
The free energy calculation for multiple substitutions is intractable using the current technology
due to the combinatorially increasing calculation load for multiple substitutions. The issue of
multiple substitutions is here addressed by assuming that the effect of immune evasion is well
represented by the sum of the contribution in each substituted site in epitope B. Data indicate the
independence of the immune evasion effect of the sites in epitope B.3 We may, thus, assume that
the free energy difference of the multiple substitution is the sum of the individual ∆∆G values
available in Table 1 plus a minor correction term.
4.5 Prediction of Future Virus Evolution
The result of this work quantifies the reduction of the binding constant of antibody to virus for
substitutions in epitope B with larger ∆∆G values and higher ranks of substituting amino acids. A
newly emerging virus strain with larger antibody binding free energy difference has a greater prob-
ability to become the dominant strain in the next flu season. Note that due to random fluctuations
in the large phase space of possible substitutions, actual trajectories deviate from the trajectory
determined by choosing sites and substituting amino acids with greatest free energy differences.
With a three dimensional structure of hemagglutinin of the current circulating virus and binding
antibody, one is able to calculate the free energy landscape for all the possible single substitutions
in the dominant epitope and estimate the a priori escape probabilities in the next season. The dom-
inant circulating influenza strain usually possesses amino acid substitutions from the vaccine strain
against which memory antibodies are generated. Usually these substitutions disrupt the antibody
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Figure 3: Two fixed substitutions G129A and E190D generated by Monte Carlo simulation of
epitope B using Eq. (28). Also plotted are two historical fixed substitutions in epitope B: T155Y
fixed between 1971 and 1973, and N188D fixed between 1970 and 1973. The frequency data
of historical substitutions are from Shih et al.47 The origin of time axis is 1968. One thousand
generation of the H3N2 virus is approximately one year. Figure 3(a) Substitution G129A causing
the free energy difference ∆∆G = 3.33± 0.29 kcal/mol is fixed by the simulation. The rank of
the free energy difference of G129A is 12 in 19 possible substitutions in site 129. Figure 3(b)
Substitution E190D with ∆∆G = 18.75±0.32 kcal/mol. The rank is 1 in 19 possible substitutions
in site 190.
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Figure 4: Two fixed substitutions N188D and V196D generated by Monte Carlo simulation of
epitope B using Eq. (29). Two historical fixed substitutions T155Y and N188D are also plotted,
and data are from Shih et al.47 Figure 4(a) Substitution N188D causing the free energy difference
∆∆G = 19.77± 0.37 kcal/mol is fixed by the simulation. The rank of the free energy difference
of N188D is 1 in 19 possible substitutions in site 188. Figure 4(b) Substitution V196D with
∆∆G= 9.25±0.34 kcal/mol. The rank is 5 in 19 possible substitutions in site 196. The proportions
of substituting amino acids are represented by different line types.
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binding process by decreasing the binding constant, as shown in Table 5. Thus one can predict
vaccine effectiveness by evaluating the antibody binding constant against the dominant circulat-
ing strain, which is acquired by calculating free energy difference of the amino acid substitutions
between the vaccine strain and the dominant circulating strain.3 More accurate predictions of evo-
lutionary pattern of virus as well as epidemiological data such as vaccine effectiveness may be
obtained by optimally mapping the free energy landscape to the fitness landscape and taking into
account random factors such as genetic drift in the evolution process.
5 Conclusion
We introduced the Einstein crystal as a technology to improve the results of free energy calcula-
tion. By calculating the free energy difference of each amino acid substitution, we obtained the
free energy landscape for substitutions in epitope B of hemagglutinin. There is notable variation
between the values of free energy differences of different substitutions at different sites, because
the identities of original and substituting amino acids, as well as the locations of amino acid sub-
stitutions, affect to differing degrees the antibody binding process. In this free energy landscape,
we suggest that virus tends to evolve to higher ∆∆G values to escape binding of antibody. Coun-
terbalancing this selection is random drift. Historical amino acid substitutions in epitope B and
Monte Carlo simulations of the virus evolution using the free energy based virus fitness, in which
random genetic drift of the virus adds statistical noise into the virus evolution process, showed that
selected substitutions are biased to those with positive ∆∆G values.
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